

# Acute Kidney Injury & CRRT

(Cardiorenal Syndrome )

**James B. Wetmore, MD, MS**

Associate Professor of Medicine, KUMC Division of Nephrology  
Director of Inpatient Dialysis, Univ. of Kansas Hospital

## Outline

- Epidemiology of AKI in the CTICU
- Risk factors for AKI & what actually happens to the kidney after cardiac surgery
- Strategies and common medications involved in the AKI patient in the CTICU: can we ameliorate AKI?
- Summary and personal recommendations

## The Wizard of Oz


(American Film Industry ranking #6 all-time)



## Paradigm Shifts: Unlearning the Learned

- For many years (decades?), we were taught that if PRBCs were needed, transfuse 2 units
- Conversation w/ gen'l surgeon while moonlighting:
  - Me: “The patient needs PRBCs; I’d like to give a unit.”
  - Surgeon: “You should give 2 units.”
  - Me: “Why is that?”
  - Surgeon: “Because giving 1 unit is like spitting in the wind.”
  - Me: “Errr....OK....”

## Paradigm Shifts: Unlearning the Learned



Hebert et al NEJM 340:409, 1999

## Epidemiology of AKI in CTICU

- Published estimates of incidence vary by
  - Definition of AKI (e.g., 30% increase in Cr, 50% increase in Cr, doubling of Cr...)
  - Type of surgery (elective CABG << emergent CABG + valve surgery)
- Extreme ranges are 1%<sup>1</sup> to 50%<sup>2</sup>
- A more helpful number is 7-8%<sup>3,4</sup> when a rise in Cr of  $\geq 1$  mg/dL is used
- “Roughly 10% have a Cr increase of 1” – more if your pop'l has lots of CKD

<sup>1</sup>Rosner et al CJASN 1:19, 2006

<sup>2</sup>Dasta et al Am J Med 104:343, 1998

<sup>3</sup>Conlon et al NDT 14:1158, 1999

<sup>4</sup>Mangano et al Annals 128: 194, 1998

## How Often is Dialysis Required?

- Evidence here clusters a bit more closely: 1-2%<sup>1,2</sup> of all patients (not AKI patients)
- This would suggest that roughly 1/6 of AKI patients are “AKI-D”
- Adding valve surgery to CABG roughly triples the risk of AKI and AKI-D

<sup>1</sup> Conlon et al NDT 14:1158, 1999

<sup>2</sup> Chertow et al Am J Med 104:343, 1998

## How Does AKI Impact Mortality?

- Again, heavily dependent of AKI def'n and period studied (e.g., hospital D/C, 30-d survival, etc).
- 15-30% overall mortality with AKI is a good estimate<sup>1</sup>
- Dialysis-requiring AKI (AKI-D) is ominous – 40-60%<sup>1,2</sup>
- AKI-D increases mortality rate by ~ 8-fold (multivariable-adjusted)<sup>3</sup>
- In-hospital mortality 1% (no AKI) vs 19% (AKI) vs 63% (AKI-D)<sup>4</sup>


<sup>1</sup>Rosner et al CJASN 1:19, 2006

<sup>2</sup>Stafford-Smith et al Curr Opin Crit Care 15:498, 2005

<sup>3</sup>Chertow et al Am J Med 104:343, 1998

<sup>4</sup>Mangano et al Annals 128: 194, 1998

## Slight Rises in Cr Impact Mortality




Lassnig et al JASN 15:1597, 2004

## Long-Term Impact of AKI on ESRD

- There's great interest in past few years about CKD and ESRD following AKI
- Not specific data in post-CPB patients – but good epidemiologic data on AKI as a whole

## Long-Term Renal Impact of AKI

- The 2000 5% Medicare Beneficiary Sample was used to examine individuals  $\geq 67$  ( $n = 233,803$ )
- 2-yr F/U
- 5.3 per 1000 developed ESRD



Ishani et al JASN 20:223, 2009

## Long-Term Renal Impact of AKI

|                  |       | Hazard Ratio           |
|------------------|-------|------------------------|
| AKI and CKD      |       |                        |
| both AKI and CKD | 79.45 | 41.19 (34.58 to 49.08) |
| AKI only         | 24.52 | 13.00 (10.57 to 15.99) |
| CKD only         | 19.88 | 8.43 (7.39 to 9.61)    |
| no AKI or CKD    | 2.08  | 1.00                   |

Ishani et al JASN 20:223, 2009

## The Kidney After Cardiac Procedures: AKI Risk Factors

Table 1. Risk factors associated with ARF<sup>a</sup>

| Patient-Related                       | Procedure-Related              |
|---------------------------------------|--------------------------------|
| Female gender                         | Length of CPB                  |
| Chronic obstructive pulmonary disease | Cross-clamp time               |
| Diabetes                              | Off-pump <i>versus</i> on-pump |
| Peripheral vascular disease           | Nonpulsatile flow              |
| Renal insufficiency                   | Hemolysis                      |
| Congestive heart failure              | Hemodilution                   |
| LV ejection fraction <35%             |                                |
| Need for emergent surgery             |                                |
| Cardiogenic shock (IABP)              |                                |
| Left main coronary disease            |                                |

<sup>a</sup>LV, left ventricular; IABP, intra-aortic balloon pump; CPB, cardiopulmonary bypass.

<sup>1</sup>Rosner et al CJASN 1:19, 2006


## The Kidney After Cardiac Procedures: Pathophysiology

| Preoperative          | Intraoperative            | Postoperative           |
|-----------------------|---------------------------|-------------------------|
| Lack of renal reserve | Decreased renal perfusion | Systemic inflammation   |
| Renovascular disease  | hypotension               | Reduced LV function     |
| Prerenal azotemia     | lack of pulsatile flow    | Vasoactive agents       |
| recent diuresis       | vasoactive agents         | Hemodynamic instability |
| NPO status            | anesthetic effects        | Nephrotoxins            |
| impaired LV function  | Embolic events            | Volume depletion        |
| ACEI/ARB              | CPB-induced inflammation  | Sepsis                  |
| Nephrotoxins          | Nephrotoxins              |                         |
| intravenous contrast  | free hemoglobin           |                         |
| other medications     |                           |                         |
| Endotoxemia           |                           |                         |
| Inflammation          |                           |                         |

<sup>a</sup>ARF, acute renal failure; NPO, nothing by mouth.

<sup>1</sup>Rosner et al CJASN 1:19, 2006

## The Kidney After Cardiac Procedures: Pathophysiology



<sup>1</sup>Rosner et al CJASN 1:19, 2006

## Risk Stratification: The Cleveland Clinic AKI Scoring System<sup>1</sup>

| Risk Factor  | Points |
|--|--------|
| Female gender  | 1      |
| Congestive heart failure                                     | 2      |
| LV ejection fraction <35%                                    | 1      |
| Preoperative use of IABP                                     | 2      |
| COPD   | 1      |
| Insulin-requiring diabetes                                   | 1      |
| Previous cardiac surgery                                     | 1      |
| Emergency surgery  | 2      |
| Valve surgery only (reference to CABG)                       | 1      |
| CABG + valve (reference to CABG)                             | 2      |
| Other cardiac surgeries                                      | 2      |
| Preoperative creatinine 1.2 to <2.1 mg/dl (reference to 1.2) | 2      |
| Preoperative creatinine >1.2 <sup>b</sup>                    | 5      |

<sup>a</sup>COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass graft. From Thakar *et al.* (30).

<sup>b</sup>Minimum score = 0; maximum score = 17.

<sup>1</sup>Thakar et al JASN 16:162, 2005

## Timing of Events in AKI

- When to call the nephrologist
  - No consensus; nephrologists argue
  - If calling when dialysis needed, too late (in an ideal scenario)

## Timing of Events in AKI: Concepts

- When dialysis is commenced?
  - No consensus; nephrologists argue
  - From 2000-2010, trend was to start early (BUN > 40 mg%)
  - BUN alone is frequently the least important metric
  - K > 5.0, pH < 7.2, rising vent support (>60% FIO<sub>2</sub>), 6+ hours of anuria warrant a consult in most instances
  - Increased vent support: though many insults to gas-exchange are not due to volume overload, a dialyzer allows you to address what you can
  - What is overall direction of the patient? (“If they are going to be worse tomorrow then they are today, start today”)

## Dialysis: Conceptual Issues

- Modalities:
  - “conventional” intermittent hemodialysis (IHD)
  - slow low efficiency extended dialysis (SLED)
  - continuous (CRRT)
- Conceptualization of dialysis is important for non-nephrologists
  - Clearance (BUN and other toxins)
  - Electrolyte & acid-base control
  - Ultrafiltration

## Off- vs. On-Pump CPB

- CABG, but not valve replacement, can be done off-pump (OP)
- Potential benefits of OP-CABG
  - Less inflammation, oxidative stress, and C’ activation induced by the pump
- Potential debits of OP-CABG:
  - Greater hemodynamic instability


## Off- vs. On-Pump CPB

- Largest study was an RCT of 2200+ patients
- Vast majority of patients w/o CKD
- AKI not an endpoint, but dialysis requirement was
- No difference in requirement for HD
- Most metanalyses reflect this; more studies with CKD patients are required

Shroyer et al NEJM 361, 1827, 2009

## Off- vs. On-Pump CPB

- Best study in CKD randomized 116 patients to on- vs. off-pump CABG.
- Mean Cr 1.45, mean eGFR  $\approx$  52 mL/min
- 3 in on-pump, 0 in off-pump required HD



Sajja et al, J Thorac CV Surg 133:378, 2007

## Medications Involved in AKI

- NAC (N-acetylcysteine)
- Dopamine
- Fenoldopam
- ANP (atrial natriuretic peptide)
- Lasix

## Preoperative NAC

- The evidence for N-acetylcysteine is extremely variable
- >24 studies and  $\geq$  3 metaanalyses have been performed
- A consensus around proof of efficacy simply has not emerged
- Even metaanalyses differ in their findings!

## Perioperative NAC

- Most promising evidence is for high-dose NAC (1200, vs 600, mg), particularly in IV form
- One study<sup>1</sup> showed benefit of ↓ AKI with 1200 mg IV before emergent angioplasty for MI
- Another<sup>2</sup> showed decreased circulating oxidative stress markers with high-dose oral (no AKI benefit)
- Oral NAC is considered “harmless” but even oral NAC is associated with anaphylaxis, rates are much higher in IV

<sup>1</sup>Marenzi et al NEJM 354:2273, 2006

<sup>2</sup>Thiele JACC 55:2201, 2010

## Role for Dopamine

- At low doses, dopamine (1-3 ug/kg/min) increase renal blood flow in experimental models and increases naturesis/diuresis ( $\beta_1$  at 5-10,  $\alpha_1$  at 10-20)
- This does not appear to be the case in humans; it seems to have a pressor effect at <5.
- Studies repeatedly show that is not effective in reducing AKI<sup>1-3</sup>

<sup>1</sup>Denton et al KI 50: 4, 1996

<sup>2</sup>Tang et al Eur J CT Surg 15:717, 1999

<sup>3</sup>Woo et al Eur J CT Surg 22:106, 2002

## Dopamine is Arrhythmogenic

- Dopamine is not benign
- A retrospective registry study<sup>1</sup> of 1700+ CABG patients found an OR of 1.74 for Afib or Aflutter
- An older study showed Dop. was most signif. Afib predictor<sup>2</sup>

| Effect                                  | p Value | Odds Ratio Estimate<br>(95% Confidence Interval) |
|---|---------|--|
| COPD/asthma, present vs. absent         | <.01    | 2.86 (1.85–4.42)                                 |
| Renal-dose dopamine, present vs. absent | <.01    | 1.74 (1.18–2.56)                                 |
| Age <sup>a</sup>                        | <.01    |  |
| Gender <sup>a</sup>                     | .013    |  |
| Age × gender interaction <sup>b</sup>   | .024    |  |
| Male age (10-yr increments)             |         | 1.57 (1.34–1.84)                                 |
| Female age (10-yr increments)           |         | 2.58 (1.72–3.87)                                 |

<sup>1</sup>Argalious et al CCM 33:1327, 2005

<sup>2</sup>Chiolero Thor CV Surg 39:81, 1991

## Fenoldopam

- Long-studied with both animal and human evidence suggesting higher eGFR but no major change in AKI incidence w/ the drug
- Best RCT<sup>1</sup> so far tested fenoldopam in 193 patients with  $\geq 1$  risk factor
  - Cr >1.5 mg/dL
  - Age >70 y
  - DM
  - Previous CABG
- 0.1  $\mu$ /kg/min vs. placebo as incision was made

<sup>1</sup>Cogliati et al J CT Vasc Anaesth 21: 847, 2007

## Fenoldopam

- Fenoldopam group had less AKI ( $p = 0.02$ ), defined as  $Cr \geq 2.0$ , and less need for HD ( $p = 0.004$ )

|                               | T1          | T2          | T3          | p Value |
|-------------------------------|-------------|-------------|-------------|---------|
| <b>Fenoldopam group</b>       |             |             |             |         |
| Creatinine clearance (mL/min) | 39.7 ± 7.3  | 68.1 ± 14.3 | 65.4 ± 18.4 | <0.01   |
| Urine output (mL/h)           | —           | 158 ± 56    | 150 ± 38    | NS      |
| Serum creatinine (mg/dL)      | 1.8 ± 0.4   | 1.6 ± 0.2   | 1.5 ± 0.3   | <0.01   |
| Fluid intake (mL/h)           | —           | 120 ± 10    | 115 ± 40    | NS      |
| <b>Placebo group</b>          |             |             |             |         |
| Creatinine clearance (mL/min) | 45.7 ± 12.3 | 38.6 ± 9.2  | 33.7 ± 11.2 | <0.05   |
| Urine output (mL/h)           | —           | 110 ± 47    | 88 ± 52     | NS      |
| Serum creatinine (mg/dL)      | 1.9 ± 0.3   | 2.5 ± 0.6   | 2.8 ± 0.4   | <0.03   |
| Fluid intake (mL/h)           | —           | 120 ± 25    | 126 ± 34    | NS      |

NOTE. Data are given as mean ± standard deviation.

Abbreviations: T1, before surgery; T2, 24 hours after surgery; T3, 48 hours after surgery; NS, not significant.

A “definitive” RCT of 1000 patients is currently underway (NCT00621790)

Cogliati et al J CT Vasc Anaesth 21: 847, 2007

## ANP: The Most Promising Intervention to Date

- Peptide made by atria; there is a human recombinant form (hANP)
- Previous small hints of promise; approved in Japan for AKI prevention
- Three fairly recent RCTs<sup>1-3</sup> and a metaanalysis<sup>4</sup> have recently all suggested benefit
- The best one in CABG patients<sup>3</sup> involved randomizing 504 patients to hANP at 0.02 µg/kg/min


<sup>1</sup>Mentzer et al JACC 49:716, 2007

<sup>2</sup>Sezai et al JACC 54:1058, 2009

<sup>3</sup>Sezai et al JACC 55:1844, 2010

<sup>4</sup>Nigwekar et al J CT Vasc Anaesth 23:151, 2009


## ANP in CABG for AKI Prevention



Sezai et al JACC 54:1058, 2009

## Lasix Mechanism

- Lasix works on the Na/K/2Cl pump in the thick ascending limb
- This pump is very metabolically active; theoretically, poisoning it could ↓ metabolic demands





## Lasix Decreases Time on Ventilator

- RCT of 1000 patients randomized to “liberal” vs. “conservative” fluid management in the MICU
- The conservative group (naturally) got much more diuretics
- At 7 days, conservative group was ~ -100 cc fluid balance; the liberal (“traditional”) group was +7 L
- No difference in mortality

NHLBI ARDSNet NEJM 354:2564, 2006

## Lasix Decreases Time on Ventilator

| Outcome  | Conservative Strategy | Liberal Strategy | P Value |
|--|-----------------------|------------------|---------|
| Death at 60 days (%)                                   | 25.5                  | 28.4             | 0.30    |
| Ventilator-free days from day 1 to day 28 <sup>†</sup> | 14.6±0.5              | 12.1±0.5         | <0.001  |
| ICU-free days <sup>‡</sup>                             |                       |                  |         |
| Days 1 to 7  | 0.9±0.1               | 0.6±0.1          | <0.001  |
| Days 1 to 28   | 13.4±0.4              | 11.2±0.4         | <0.001  |

NHLBI ARDSNet NEJM 354:2564, 2006

## Volume Overload May Be Associated with Mortality



- Fluid overload may result in endothelial injury, volume overload, and other deleterious events in critical illness<sup>1</sup>
- An observational study of >600 patients at 5 AMCs assessed risk of fluid overload in AKI and AKI-D<sup>2</sup>

<sup>1</sup>Prowle et al Nat Rev Nephrol 6:107, 2010  
<sup>2</sup>Bouchard et al KI 76:422, 2009

## Volume O/L May Be Assoc. w/ Mortality

a, dialyzed  
OR = 2.1

b, non-dialyzed  
OR = 3.1



Bouchard et al KI 76:422, 2009

## Lasix in AKI: The Nuances

- Non-oliguric AKI has a better prognosis than oliguric/anuric AKI
- This does **not** mean that “converting” a patient to a better state improves AKI or other outcomes.
- 3 older trials all showed no difference in outcomes with lasix<sup>1,2,3</sup>


<sup>1</sup>Kleinknecht et al Nephron 17: 51, 1976

<sup>2</sup>Brown et al Clin Nephrol 15:90, 1981

<sup>3</sup>Shilliday NDT 12:2592, 1997

## Lasix May Be Harmful

- 126 cardiac surgery patients with normal renal function randomized to lasix, dopamine, or placebo




Lassnig et al JASN 11:97, 2000

## Lasix and Forced Euvolemic Diuresis

- Perhaps it is throughput of the kidney, not diuresis *per se*, that is helpful
- This was tested in an RCT of 138 patients getting contrast w/ cardiac cath<sup>1</sup>
- All patients had CKD (Cr ≥ 1.7), and were assigned saline alone vs (saline + mannitol + lasix)
- Diuresis group matched mL-for-mL
- Outcome: 25% increase in Cr within 48 hrs

<sup>1</sup>Majumdar AJKD 54:602, 2009

## Lasix and Forced Euvolemic Diuresis



<sup>1</sup>Majumdar AJKD 54:602, 2009

## Lasix and Forced Euvolemic Diuresis

- Trial terminated for futility after < 50% enrollment
- AKI occurred in 50% in intervention arm vs. 23% in controls ( $P = 0.03$ , adj. OR 3.7)
- Within hours, Cr increase 0.8 in intervention arm vs. 0.2 in controls

<sup>1</sup>Majumdar AJKD 54:602, 2009

## Lasix: Summary

- The kidney is smarter than any doctor
- While lasix will decrease vent/ICU days, it will not help in AKI prevention; if anything, it is likely to be harmful in at-risk kidneys
- Lasix should be used to protect the cardio-pulmonary status; there is no evidence for any renoprotective effects

## What Information Can the ICU Nurse Provide for the Nephrologist?

- Hemodynamic trends
- Filter performance
- Citrate anticoagulation

## Hemodynamics

- Nephrologists, as consultants, generally work with primary physicians on UF goals
- Nephrologists sometimes have a differing perspective
  - “Is that infiltrate on CXR really pulmonary edema? We’ll do what we can, but...”
  - “We can pull fluid off, but are you prepared to support the patient with pressors? Are you prepared to treat the consequences of a tachyarrhythmia?”
- When asked to aggressively UF, nurse input is critical

## Hemodynamics

- Discussion with the nurse about the (hemodynamic) course of the patient is essential
  - What is the trend in BP, HR? -- timecourse of interest is minutes to hours
  - What is trend in other pressors or cardioactive meds (CCU)?
  - What is overall trend in patient's course (better/worse/same)?
  - What events are known to be planned for the day (OR or procedure, extubation, etc)?

## Hemodynamics

- As UF rate is increased (say, 100cc/hr to 150cc/hr), BP/HR must be carefully watched
- At the first sign of a true trend in BP or HR, nephrologist should be notified
- While not rigorously studied, a UF "holiday" of perhaps 4 hrs is probably appropriate – i.e., no UF to allow for vascular refill, followed by a re-challenge with UF
- If the vent support is high, or if the primary team accedes to increase in pressors, UF holiday is probably not optimal course

## Filter Performance: Clotting and Clogging

- Clotting causes filter failure due to obstruction of the membrane pores from the molecular products of the clotting cascade
- Clogging is an entity – at least theoretical and perhaps of clinical significance – in which inflammatory mediators degrade filter performance
  - Some claim this process to be beneficial since these mediators are components of SIRS

## Filter Performance

|  |  |  |
|--|--|--|
| TMP<br>( $< 450$ )   | TransMembrane Pressure =<br>[Filter Pressure + Return Pressure] / 2 – Effluent Pressure  | <b>CLOGGING:</b> Measures pressures in the middle of the filter – the force necessary to pull fluid across the membrane – isolates the problem to membrane clogging versus hollow capillary fibers clogging.   |
| $\Delta P$<br>Delta P<br>( $< 100$ change from baseline $\Delta P$ ) | "Filter Pressure Drop"<br>$\Delta P = \text{Filter Pressure} - \text{Return Pressure}$<br><br>(Baseline $\Delta P$ is pressure with initial BFR) | <b>CLOTTING:</b> Increase in filter pressure alone insufficient to rule-out if the problem is the actual filter or return line pressure.<br>1. $\uparrow$ filter pressure + $\uparrow$ $\Delta P$ = Filter pressure increasing while return pressure remains normal. Therefore, cause is due to clotting of the filter and <u>not</u> a return line problem.<br>2. Unchanged filter pressure + $\uparrow$ $\Delta P$ = Filter is patent, but there may be a return line problem. |

Note that the delta P should be recorded at the beginning of the filter life and at other "natural" intervals, like beginning of a shift.

If the delta P increases beyond 100 (a delta-delta P!) this suggests clotting is occurring

A rise in TMP (which should be  $< 450$ ) suggests clogging

## Citrate: Special Challenges

- Citrate is used to chelate  $\text{Ca}^{2+}$ , a component of the clotting cascade, in the circuit
- Citrate is introduced prefilter, depleting Ca locally
- A separate  $\text{Ca}^{2+}$  infusion (thru another central line) is used to reverse this
- Blood flow rate affects citrate rate, and citrate rate affects  $\text{Ca}^{2+}$  rate – true cascade

## Citrate: CRRT Prescription Cascade

- b. Infuse at \_\_\_\_\_ mL/hr (initiate at 1.5 times BFR, not to exceed 300 mL/hr unless ordered by Nephrologist)  
{Example: BFR is 180 mL/min. The ACD-A infusion would be started at  $1.5 \times 180 = 270$  mL/hour}
- c. Titrate citrate ACD-A infusion rate per parameters (see hyperlink) using post-filter (blue port) ionized calcium.
- d. Stop BOTH Citrate and Calcium infusions any time the blood pump is not running including when the filter clots and when CRRT is discontinued.
- \*\*Attach PDF of "Citrate Infusion Adjustment" table as hyperlink on MAR\*\*
- calcium chloride 8g/NS 1,000 mL IV infusion, Titrate
- a. Infuse via central line only
- b. Start calcium chloride infusion at \_\_\_\_\_ mL/hr. Initial rate should be 40% of citrate infusion rate.
- \*\*\*Example: if BFR=100mL/min, citrate infusion rate=150 mL/hr and calcium chloride infusion rate= 60 mL/hr
- \*\*\*Example: if BFR=150mL/min, citrate infusion rate=225 mL/hr and calcium chloride infusion rate= 90 mL/hr
- c. Titrate calcium chloride infusion rate per parameters (see hyperlink) using systemic ionized calcium.

## Citrate: Calcium and Citrate Adjustments

| Systemic Ionized Calcium (mmol/L) | Calcium Infusion Adjustment   |
|-----------------------------------|---|
| <0.85                             | Rate 15 mL/hr, Give 1 gram calcium gluconate(4.5 mEq calcium)IV AND call renal fellow |
| 0.85 – 0.94                       | Rate 10 mL/hr & Give 1 gram calcium gluconate IV                                      |
| 0.95 – 1.09                       | Rate 5 mL/hr  |
| 1.10 – 1.20 (Optimum Range)       | No Change   |
| 1.21 – 1.35                       | 5 mL/hr   |
| >1.35                             | 10 mL/hr and call renal fellow  |

### CRRT Citrate Anticoagulation Protocol

Titrate citrate ACD-A infusion rate per parameters below using post-filter (blue port) ionized calcium:

| Post Filter (blue port) Ionized Calcium (mmol/L) | Citrate Infusion Adjustment |
|--|-----------------------------|
| < 0.25   | Decrease rate by 5 mL/hr    |
| 0.25 - 0.45 (Optimum Range)                      | No Change                   |
| 0.46 – 0.5                                       | Increase rate by 5 mL/hr    |
| > 0.5  | Increase rate by 10 mL/hr   |

## Citrate: Special Challenges

- A patient in steady state should require only a few dose changes – perhaps 3 – of  $\text{Ca}^{2+}$  before equilibration
- If the systemic ionized  $\text{Ca}^{2+}$  is, say, 0.93 mmol/L, this doesn't look too bad at first glance
- Nurse gives an amp and increases rate by 10 mL/hr

## Citrate: Special Challenges

- 1<sup>st</sup> reading: 0.93 → amp given and rate increased
- 2<sup>nd</sup> reading: 0.92 → amp given and rate increased
- 3<sup>rd</sup> reading 0.94 → amp given and rate increased
- This is a warning sign! The  $\text{Ca}^{2+}$  is going somewhere!
- The nephrologist should be made aware that by the end of the first shift, steady-state has not been achieved
- The nephrologist should ask – but the nurse should tell

## “Citrate Lock”

- Anion-gap metabolic acidosis
- Persistently low systemic (patient) ionized  $\text{Ca}^{2+}$ , refractory to calcium boluses
- A rising total serum calcium.
- Typically seen in patients with liver failure (citrate not metabolized to bicarbonate, so citrate is binding ionized  $\text{Ca}^{2+}$  -- while total  $\text{Ca}^{2+}$  increases as it is dumped in
- Citrate must be held or ceased

## Other Citrate Complications

- Alkalemia can increase by the citrate infusion
- ABG or VBG will show steady rise in pH – 7.45, 7.50, even 7.60 over 6-12 hours
- Nephrologist should be ordering extra VBGs on citrate patients – ICU teams won't be thinking of this
- Nephrologist should ask for gases – but nurse should tell!

## Other Citrate Complications

- Long-term, changing protocols to use less citrate while maintaining anticoagulation is the answer
- Short-term, holding citrate for several hours then resuming citrate at 70% of previous rate is appropriate

## Lowering the Risk of Postoperative AKI: Personal Recommendations

- For non-emergent procedures, hold diuretics and ACE-I/ARBs for 2-3 days prior and thereafter (admittedly, not possible in decompensated CHF)
- Hydration with IVF (Na bicarb preferred) for several hours before in CKD patients (eGFR < 60 mL/min); no fluid if CKD not present (to reduce dangers of volume O/L)
- Use diuretics to protect cardiopulmonary status only; do not give solely for oliguria, rising Cr, etc.
- Fluid challenge certainly reasonable in oliguria if pulm status will tolerate
- Follow the literature on ANP, but dopamine and fenoldopam have no demonstrated utility

Thanks for your attention!

Questions?

### AFI top-ranking movie list (by critical acclaim)

- #6 Wizard of Oz (Judy Garland)
- #5 Lawrence of Arabia (Peter O'Toole)
- #4 Gone with the Wind (Clark Gable)
- #3 The Godfather (Marlon Brando)
- #2 Casablanca (Humphrey Bogart)
- #1 Citizen Kane (Orson Welles)